3D Biology Based T Cell-Mediated Killing Assays

Creative Biolabs provides T cell-mediated killing assays based on long-standing cutting-edge research on the role of the immune system, particularly T cells, in the recognition and elimination of tumor cells using an emerging 3D biology-based modeling platform.

Assay process at Creative Biolabs

Sample collection. Samples containing T cells are collected from blood or tumor tissue and personalized 3D normal or tumor models are created.
T cell activation. In a well-equipped platform dedicated to 3D model application experiments, operators expose the models to tumor antigens to induce T-cell expansion and activation.
Mediated tumor killing. Activated T cells have a highly specific response to tumor antigens within the model, thereby mediating specific recognition and killing of tumor cells expressing these antigens.
Comprehensive testing is based on multiple dimensions. Detecting changes in molecular markers or gene levels in killed 3D in vitro tumor models.

Flow cytometry detects the proportion of apoptotic and dead cells to interpret the precise characterization of death pathways, combined with the labeling of target cells to probe the status of specific cells.
Methods based on the detection of compounds that release labeled radioisotopes after cell lysis can be used to detect cell lysis.
Measurement of post-kill lactate dehydrogenase and other dead cell releases to assess T cell-dependent killing efficacy.
The combined usage of immunohistochemistry, genome-wide association studies, and other assays such as scRNA-seq improves the ability and accuracy of analysis of T cell subpopulation-mediated killing from multiple dimensions.

Fig. 1 Immune enhancement induces T-cell activation and tumor killing.¹

Applications and Advantages

Applications

Used to study the effectiveness of tumor immunotherapy as an indicator to assess the immune status of a personalized model. Examples include immune checkpoint blockade therapy or CAR-T therapy.
Used to diagnose tumors, predict disease progression and control, and monitor disease recurrence to guide treatment decisions.

Advantages

Highly personalized assessment.

T cell-mediated tumor-killing assays performed in the 3D platform capture the T cell response to heterogeneous tumor cells, providing a reliable way to assess disease status and the effectiveness of interventions.

Sensitive and scalable detection

The assay is capable of identifying minor T cell-associated immunological diversity and supports customized scalability studies.

Creative Biolabs helps customers validate T cell-mediated toxicity activity in 3D ex vivo-based models through a variety of methods that can measure the toxicity potential of T cells. Please contact us to address your needs.

Reference

Votanopoulos, Konstantinos I., et al. "Model of patient-specific immune-enhanced organoids for immunotherapy screening: feasibility study." Annals of Surgical Oncology 27 (2020): 1956-1967.

Research Model

3D Biology Based Biomarker Discovery

3D Biology Based Drug Discovery and Development

3D Biology Based Toxicity Evaluation

Supporting Assays

Related Sections:

Research Model

Services

USA

Germany

Online Inquiry